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Blood  coagulation  Factor X is a serine protease re- 
quired  for  both the intrinsic and extrinsic pathways of 
coagulation.  The  gene  for  Factor X spans 27 kilobases 
and is located  on  chromosome 13, in close  proximity  to 
the gene  encoding  Factor VII. Expression of  Factor X 
is restricted to the liver. We have characterized the 
human  Factor X promoter  by  mapping  the  start sites 
of transcription  and carrying out  a  functional analysis 
of the  promoter.  The first 279 base pairs (bp)  of 5’- 
flanking sequence upstream from the first AUG are 
sufficient to  confer  maximal  promoter activity in 
HepG2 cells. Protein-binding sites within the 279-bp 
fragment are defined  using gel mobility shift assays. 
Mutagenesis  of two specific sequences within the 279- 
bp  fragment (CCAAT at -120 to -116, and  ACTTTG 
at -56 to -61), results in loss of ability to  bind  proteins 
from  a HepG2 nuclear extract, and  profound  reduction 
in promoter activity of the 279-bp fragment. We con- 
clude  that  these two protein-binding sites are critical 
for the activity of the  Factor X promoter. 
The vitamin K-dependent procoagulant proteins,  Factors 
11, VII, IX, and X, are  the major enzymes of the coagulation 
cascade. Like the cofactors V and VIII, their expression is 
restricted to the liver, i.e. is tissue-specific (I). Recently, a 
number of liver-specific transcription factors have been iso- 
lated  and characterized (2-7), but  the interactions of these 
elements with the genes for the vitamin  K-dependent  clotting 
factors remain largely unexplored. Whether there is any  de- 
gree of coordinate regulation of the vitamin K-dependent 
factors is also unknown. The  human Factor IX and Factor I1 
promoters have been characterized to some extent (8-lo), and 
for the  IX promoter, Crossley and Brownlee (10) have shown 
a binding site for the  transcription factor C/EBP. The Factor 
X promoter has not been previously characterized; indeed, 
very little 5”flanking sequence has been published to  date 
(11). Factor  X is an  attractive paradigm for study of regulation 
of the vitamin  K-dependent  clotting factors, since, in  contrast 
to  the situation for Factor IX, a well-characterized cell line 
exists, the HepG2 cell line, which expresses Factor X (12). In 
this paper, we report the functional  characterization of the 
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human Factor X promoter, including the sequence of 745 bp’ 
of flanking DNA, the  start  site of transcription, activity of 
the promoter using a  reporter gene assay, and delineation of 
specific protein-binding  domains within the promoter. One of 
these  protein-binding regions, conserved in  the promoters of 
Factors IX  and VII, may be involved in  coordinate regulation 
of the genes encoding the vitamin  K-dependent  clotting fac- 
tors. Mutagenesis of the protein-binding  domains described 
here is associated with loss of the protein-binding  property 
and loss of promoter activity as well. 
MATERIALS AND  METHODS 
Anchored  PCR 
Anchored PCR was carried out using the procedure of Loh et  al. 
(13) with modifications. Using 0.1 pg of human liver poly(A+) RNA 
(gift of Dr. D. W. Stafford, University of North Carolina at Chapel 
Hill) as  starting material, first strand cDNA  was synthesized using a 
Factor X-specific primer (5’-CCAGAATTCATTCGTCTTGTCGCT 
GTCCTC-3’, located 244 bp downstream from the  1st AUG) and 
200 units of Moloney murine leukemia virus H- reverse transcriptase 
(Bethesda Research Laboratories), which lacks RNase H activity. 20 
units of RNasin was included in this reaction. Excess primer and 
unincorporated deoxynucleosides were  removed by two passages 
through Sephadex G-50, and first strand cDNA  was then tailed with 
poly(G) using terminal deoxynucleotidyl transferase (Boehringer 
Mannheim). The tailed FX cDNA was amplified using a second 
Factor X-specific primer (5’-TGGCCTGCTCCCTGCGGATGAAC 
AGACTTT-3’, located 95 bp downstream from the  1st AUG) and a 
GGATCCCCCCCCCCCCCC-3’) and AN (5”GCACAAGCTTGAA 
mixture of nonspecific primers ANC (5”GCACAAGCTTGAATTC 
TTCGGATCC-3’)  in  a  ratio of 1 : l O  for the poly(G) end of the 
cDNA. After amplification, the PCR product was gel-purified and 
subcloned into an M13 vector by blunt-end ligation for sequence 
analysis (14). 
SI Nuclease  Analysis 
S1 nuclease analysis was carried out using the procedure of Sharp 
et al. (15). A 357-base single-stranded DNA probe, beginning 279 
bases upstream from the first AUG and continuing through exon 1, 
was 5’ end-labeled and hybridized to 12.5 pg of total human liver 
RNA. After treatment with 50 units of S1 nuclease (Bethesda Re- 
search Laboratories) at 30 “C, the DNA-RNA heteroduplexes were 
electrophoresed on  a  6%  denaturing acrylamide gel. Nucleotide se- 
quence was run on the same gel as  a size marker. Hybridization of 
the probe to yeast tRNA (Boehringer Mannheim) served as  a negative 
control. 
Isolation and Characterization of 5”Flanking Region 
of Human Factor X 
Previously published data on the 5’-flanking region of human 
Factor X included only 281 bp upstream from the first AUG (11). 
This sequence was amplified from human genomic  DNA using 
primers based on the published sequence. To obtain additional 5‘- 
flanking sequences, 2.8 X lo5 cosmid clones from a human genomic 
The abbreviations used are: bp, base pair(s); kb, kilobase pair(s); 
PCR, polymerase chain reaction; hGH, human growth hormone; 
SEAP, secreted alkaline phosphatase plasmid; HEPES, 442-hydrox- 
yethy1)-1-piperazineethanesulfonic acid. 
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placenta library (Stratagene,  La  Jolla, CA)  were screened using the 
available 5”flanking sequence (-279 bp + +12) as a probe. One 
positive cosmid clone was obtained. Based on restriction  analysis and 
PCR amplification of downstream exons  within the clone (exon 1 was 
present, exon 2 was not),  the clone appears to contain at least 10 kb 
of 5”flanking sequence. A 3.5-kb BamHI fragment, spanning the 
region from 2.8 kb upstream from the first AUG to  the first intron, 
was subcloned into pBR322, sequenced, and used as  starting material 
for  preparing  transfection  constructs. The sequencing strategy  con- 
sisted of synthesizing  a sequencing primer based on the known 5’- 
flanking sequence, and preparing  subsequent  primers based on  data 
from each run  to “walk” further upstream. 
Tissue Culture 
HepG2 cells (16) (originally from Wistar Institute)  and HeLa cells 
(17) were obtained from the Tissue  Culture Facility in the Lineberger 
Cancer Research Center at  the University of North Carolina-Chapel 
Hill. The following materials were also obtained  through the Tissue 
Culture Facility in the Lineberger Cancer Research Center at UNC- 
CH: fetal bovine serum (HyClone Laboratories,  Inc.), Eagle’s minimal 
essential medium (containing Eagle’s salt  and L-Glutamine), phos- 
phate-buffered saline (pH 7.5), 0.4% trypan blue stain (Bethesda 
Research Laboratories), 0.05% trypsin, 0.53 mM EDTA.4Na (Be- 
thesda Research Laboratories),  sterile  H20  (endotoxin-free),  dimethyl 
sulfoxide (Sigma), and  CaCI2.2Hz0 (cell culture grade, Sigma). 
HepG2 cells were grown in Eagle’s minimal essential medium supple- 
mented with 10% fetal calf serum, 0.01% penicillin, and 0.01% 
streptomycin. HeLa cells were  grown in Dulbecco’s minimal essential 
medium-H with 10% fetal calf serum, and 0.025% kanamycin. 
Reporter Gene Assays 
Preparation of Constructs inpOGH Vector-The  pOGH vector (18) 
employs secretion of hGH into  the medium as  an assay for eukaryotic 
promoter strength. The vector contains hGH structural sequences 
cloned into the BamHI-EcoRI sites of pUC12. For the assays for 
Factor  X promoter activity, varying lengths of Factor X 5”flanking 
sequence were cloned into  the HindIII-Xbal site of pOGH by direc- 
tional cloning (see Fig. 1). The flanking sequence fragments were 
generated by PCR and deleted at  the 5’  end using convenient  restric- 
tion sites. The 3’ amplifying oligonucleotide contains an engineered 
XbaI site within the translated sequence, used for subcloning into 
pOGH (see Fig. 2). All inserts contain the entire 5’-untranslated 
sequence. The PCR-generated fragments were sequenced to verify 
that no errors had been introduced in the amplification step. 
hGH Assay-Levels of hGH in  the medium were measured with a 
solid-phase two-site radioimmunoassay kit under the conditions rec- 
ommended by the manufacturer (Nichols Insitute Diagnostics, CA). 
The lower limit of detection of the assay is 0.5 ng of hGH/ml; the 
assay is linear in  the range of  0.5-50 ng/ml. 
Transfection Conditions-Optimal transfection  conditions were de- 
termined for each cell line using a secreted alkaline phosphatase 
plasmid (SEAP) (19). For assays of promoter activity, cells were co- 
transfected with pOGH constructs and  the  SEAP plasmid; levels of 
SEAP activity were used to normalize transfection efficiency. For 
HepG2 cells, transfection efficiency varied over a %fold range and 
for HeLa cells over as much as 5-fold. For HepG2 cells, lo6 cells in 
60-mm  tissue  culture dishes were transfected with 2 pg  of SEAP and 
2 pg  of  pOGH FX5’ by the  Capo4 precipitation method (20). After 5 
h of exposure to DNA precipitates, the cells were washed with 
phosphate-buffered  saline and fresh medium was added. Forty-eight 
hours  after  transfection, the medium was harvested to perform SEAP 
and hGH assays. For HeLa cells, optimal  transfection  conditions are 
slightly  different. 5 X lo5 cells in 60-mm tissue  culture  dishes were 
transfected with 6 pg of pOGH FX5’ and 2 pg of SEAP using the 
CaPO, method. Sixteen  hours  later the cells were washed with  phos- 
phate-buffered saline and fresh medium supplemented with 5 mM 
sodium butyrate was added. Seventy-two  hours  after  transfection, the 
medium is assayed for hGH and  SEAP. 
Preparation of Nuclear Extracts 
Approximately 1 X lo9 HepG2 cells were used to prepare the 
nuclear  extract. The cells were  grown to 50% confluence and proce- 
dures were performed as previously described (21-23). All steps were 
carried  out at 0-4 “C. Following gentle  extraction of nuclear proteins 
in  the presence of protease  inhibitors, extracts  are dialyzed, divided 
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FIG. 1. Constructs used in reporter gene assays. Varying 
lengths of Factor X promoter were subcloned into  the HindIII-XbaI 
site of pOGH by directional cloning. The Hind111 site in  the vector 
was blunt-ended with Klenow fragment. The Factor X promoter 
fragments were generated using PCR the 3’-oligonucleotide con- 
tained an XbaI site located within exon 1. The creation of the XbaI 
site does not alter  any sequences within the Factor X promoter. The 
5’ ends were generated by restriction enzymes and filled in with 
Klenow fragment if necessary. The constructs were sequenced 
through the regions of the inserts to insure that no errors had been 
introduced through cloning or PCR. 
In Vitro Synthesis of C/EBP Protein 
The cDNA of rat  C/EBP (24) was the gift of Professor S. McKnight 
(Carnegie Institution of Washington). The cDNA was released from 
pMSV and subcloned into  pSP6/T3  (BRL)  in  the same orientation 
as  the  T3 promoter. Following transcription with T3 RNA polymer- 
ase, in vitro translation was performed using a rabbit reticulocyte 
lysate system as described by the manufacturer  (Promega). Purified 
C/EBP fragment  containing the 88 COOH-terminal  amino acid res- 
idues was the gift of Dr. Z. Cao and Prof. S. McKnight of Carnegie 
Institute of Washington, Baltimore, MD. 
Gel Mobility Shift Assays 
The basic procedure is that of Chodosh et al. (25). Oligonucleotide 
probes were prepared on an oligonucleotide synthesizer (Millipore), 
annealed, and 5’ end-labeled using T4 polynucleotide kinase. Probes 
included the following: Factor X promoter sequence from -133 to 
-103 (CCAAT); same probe except CCAAT sequence changed to 
AGCTA (mCCAAT); promoter sequence from -68 to -39 
(ACTTTG); same probe except that ACTTTG  has been changed to 
GACAAT (mACTTTG);  and a probe spanning the same region of 
the promoter and containing  a single nucleotide change from wild- 
type, T-A at -52 (MT-A). These were used for both the binding and 
competition assays. Binding conditions were optimized by varying 
the ionic strength of the binding buffer and  the amount of nonspecific 
DNA or poly(dI.dC) added. For binding  reactions with HepG2 nu- 
clear extract, the DNA probe was incubated with 10 pg  of the extract 
in 24 pl of 10 mM HEPES  (pH 7.61, 40 mM KC], 3 mM MgCl,, 4% 
Ficoll, 0.5 mM dithiothreitol, and 2 pg of dI.dC for 15 min at  room 
temperature.  For  binding  reactions with purified protein  (either na- 
tive protein  or translation product), the DNA probe was incubated 
with either 5 ng of purified C/EBP fragment  or  1/25 (2 pl)  of the 
translation product from 1 pg of C/EBP  transcript  in 20 pl of 10 mM 
HEPES (pH 7.5), 50 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 
12% glycerol, 1 mg/ml bovine serum albumin,  and 0.5-1.0 pg of dI. 
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dC at room temperature for 15 min. Varying amounts of dI.dC (0.1- 
2.0 pg) or salmon sperm DNA (0-2.0 pg) were tested to determine 
optimal binding conditions. In all cases, the whole reaction was  loaded 
onto a 5% nondenaturing acrylamide gel (bis:acrylamide = 1:30) 
containing 0.5 X TBE  and 5% glycerol and run  in 0.4 X TBE  at 300 
volts at 4 "C. When retarded bands were observed, 15-150-fold con- 
centration of unlabeled oligonucleotide probes were included in the 
reaction for the competition. A double stranded DNA fragment con- 
taining the C/EBP-binding site, spanning the sequence from -178 to 
+33 of the factor IX promoter, was included as  a positive control for 
C/EBP binding (10). 
Mutagenesis of Factor X Promoter  at  Potential  Protein-binding  Sites 
Mutagenic oligonucleotides were synthesized in an oligonucleotide 
synthesizer by including the  three non-wild-type precursors at each 
step of the synthesis, so that  the sequence of the protein-binding 
region is replaced by randomly incorporated non-wild-type nucleo- 
tides. The oligonucleotide is designed such that both the 3' and  the 
5' ends contain 12 nucleotides of wild-type DNA sequence. Uracil- 
containing DNA templates were prepared by the method of Kunkel 
(26) and annealed to  the primers described above. In vitro primer 
extension was carried out using 10 units of T4 DNA polymerase (New 
England Biolabs) and 800 units  (2 pl) of T4 DNA ligase (New England 
Biolabs) and incubating at room temperature for 4 h. 1/50 to 1/20 of 
the reactions (10-25  ng of DNA) were  used to transform Escherichia 
coli wild-type strain JM 103. Mutations were identified by sequence 
analysis. 
The mutated M13 templates were subjected to PCR, and the 
resultant DNA fragments were subcloned into pOGH plasmid vectors. 
Each individual clone  was sequenced to insure that no mistakes were 
introduced into the promoter fragments during PCR and  to verify 
the DNA sequences in the mutated regions. 
RESULTS 
Start  Site of Transcription-The start site of transcription 
for  Factor X has  not previously been determined. We have 
used both  anchored PCR  and S1 nuclease analysis to map the 
start sites of transcription. Briefly, anchored PCR involves 
reverse transcription of RNA, priming with a Factor X- 
specific oligonucleotide. The reverse transcripts are tailed 
with  poly(G) using terminal deoxynucleotidyl transferase, and 
the tailed reverse transcripts are enzymatically amplified 
using another Factor X-specific primer and poly(C). The 
resulting PCR products are subcloned into M13 and se- 
quenced to disclose transcription start sites. Human liver 
poly(A+) RNA was used as  starting material. The  total  num- 
ber of Factor X clones sequenced was 21. The 21 clones 
mapped to 6 different start sites, indicated by arrows on Fig. 
2. Most of the  start sites clustered within a 20-bp region, at  
sites ranging from 13  to 33 bp upstream from the  first AUG. 
Three of the 21 clones mapped to a longer transcript, with  a 
start site 57 bp upstream from the  first AUG. S1 nuclease 
analysis confirmed these results (data  not shown), and sug- 
gested one additional transcription start site at -130 bp 
upstream from the first AUG. Based on  band  intensity, this 
appeared to be a minor start  site  and was not seen in  the 
anchored PCR clones. The finding of multiple start sites of 
transcription, by both  anchored PCR  and S1 nuclease analy- 
sis, is consistent with results previously reported for other 
TATA-less  promoters (Ref. 27 and references therein).  This 
is the first  report of the  start site of transcription of the Factor 
X gene. 
Since anchored PCR has  not been used extensively to map 
start sites of transcription, we used the technique to map the 
start  site of human  Factor  IX, as a check on the accuracy of 
the method. Using total RNA as  starting material, the exper- 
iment was performed as described above. Five clones were 
sequenced; three of these mapped to -26 and two others  to 
-10 upstream from the  first AUG. The former result (-26 
start site) is in close agreement with the  start site previously 
determined by S1 nuclease analysis by Anson et al. (28). 
-745 AGCCTCGGAA  CAGTGTGGCC  AGTGGTGGGC  AGGTCAGGAG  GGCTTCAAC  ACAGCCTGTC 
-685 CCTCCAGATG  TCACGGGAA  GGTCACTCCC  ACAGAAGTA  CGTTTTGGGG  CCATGCGGGC 
-625 RCAGAAGGTT  GGGGGTGGG  TGGGGCAGGT  GCCAGCCTGG  CCTGTGGGAG  CCATGGTGC 
-565 AGATGCCAAG  CCCCCCCCGT  GACATGAGAC  ACCTGATAC  ACCCAGAGA  GTGGCTGTCA 
-505 GCGGAAGGGC  CGCCCAGAA  CAAGCAGGG  CCTTGGGGCA  GAAGTCCTGG  CTCAGATCC 
-445 CACGCTCACT  GCCAGCGGCC  TCGGCTCAGG  CTTCTGCGCT  CTCTAAACTT  AGTTTTcTCT 
-385 TCTGGAAAAA  TGATGGGGRR  AATGATATTT  GTATGTGATT  GTGAGGACTG  AGAGTTAART 
-325 GTAAACATCT  GGAAACTACA  AATGAGCAC  GAAATGATGT  TTTATTCTT  AGAACRGAhA 
-265 GTCCCCACAC  CGCGGCCCT  GGTGACTGAT  GAGGATGAGG T T C C G p G G  CCTCTCTGGC 
-205 GCCEAGCTCT  GCCTGGGGAA  GGTGGGGCCA  GAGTGGATGT  GTTCCCAGCG  TGGTCACTCC 
- 145 CCTGCCTCGC C+CAGGTCT C G G C T M  CAGGAGGCCT A . + ~ A G T G  ATAACCACCC 
- 8 5  AGACAACAGC C A T C C C ~ C T  GGGGCGTGGA CTTTGCTCCA GCAGCC$TC C C A C T G R C G ~  
-25  CAGGGACACA  GTACTCGGCC  ACACC a i g  gQg cgc cca Ctg cac cic gic clg cic agi 
1 + (  
L 1 1  Met 
gcc icc ctg gci ggc cic cig ctg cic ggg gaa agi 
+" Ser 
FIG. 2. 5"Flanking sequence of human Factor X gene. The 
sequence reported was determined from a cosmid clone from a human 
placental library. The 281-bp immediately upstream from the  trans- 
lation start  site had been previously reported (11). The nucleotides 
in this sequence which differ from the previous report are marked 
with an asterisk.  Lower  cme denotes translated sequence. Transcrip- 
tion start sites are marked with an arrow. The location of the 
engineered XbaI site  is denoted by a diamond. The areas that were 
mutated for the gel shift and reporter gene assays are underlined. 
The fragments used as probes in the gel shift assays are enclosed in 
brackets. 
Characterization of Additional 5'-Flanking Sequence-Re- 
sults  are shown in Fig. 2. At 5 residues in  the 3' 281 bp, this 
sequence differed from that previously published (11). The 
remaining sequence data have not been previously published. 
All data presented here are  the results of at least two inde- 
pendent sequencing runs. The sequence data reported here 
have been entered  into  the GenBank of Los Alamos National 
Laboratory. 
Factor X Promoter Activity in HepG2 Cells-Following 
identification of the transcription start sites in Factor X, 
promoter activity was examined using a  reporter gene assay 
in a transient expression system. Varying lengths of 5'-flank- 
ing DNA from Factor X were cloned into  the human growth 
hormone-containing plasmid pOGH (18) (Fig. 2) and intro- 
duced into HepG2 cells by calcium phosphate transfection. 
Deletion constructs were made using appropriate  restriction 
sites or  PCR fragments; pOGH, the growth hormone plasmid 
without any 5"flanking sequence, was used as a negative 
control.  Optimal  transfection  conditions for HepG2 cells were 
first determined, and involved addition of 4 pg  of DNA X 5 h 
without glycerol shock. Transfection efficiency was monitored 
using pBC12/CMV/SEAP (19) (gift of Dr. B. Cullen, Howard 
Hughes Medical Institute, Duke University) and  the results, 
which represent the average of  4-10 transfection  experiments, 
are shown in Fig.  3A. (Numbers of transfection  experiments 
and  standard deviations for each are shown in Table I.) The 
highest levels of promoter activity were present in  the frag- 
ment containing 279 bp of DNA upstream from the  first AUG. 
The addition to  the construct of the next 109 bp upstream 
has little effect on  promoter activity. Inclusion of additional 
5"flanking sequences gradually diminishes activity, so that 
the 2.8-kb construct  has only 55% of the maximal promoter 
activity observed with the 279-bp construct. For constructs 
shorter  than  the 279-bp fragment, the 209-bp fragment again 
has close to maximal activity. Further deletions result in 
substantial loss of activity, so that  the 121-bp fragment has 
only 23% of maximal activity, and deletion of the next 13 bp 
(the 108-bp fragment)  containing the CCAAT sequence (see 
below) results  in  a 4-fold further reduction in activity. Thus, 
the major elements required for Factor X promoter activity 
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FIG. 3. Promoter  activity of dele- 
tion constructs. A,  in  HepG2  cells pro- 
moter  activity  is measured  by quantitat- 
ing growth  hormone activity in' the me- 
dium. Results reported are the average 
of 4-10 transfection experiments. The 
activity of the maximally active con- 
struct (279-bp fragment) is arbitrarily 
set at 10076, and other results are re- 
ported as a percent of the maximum. B,  
in HeLa cells maximal activity is seen 
with the 209-bp fragment,  and  other  re- 
sults are expressed as a percentage. All 
results are the average of at least two 
transfection  experiments. 
1201 1 1201 1 
A rm Ss.8 ' 0  
n1w-  n 
rm 
poGH 108 121 209 279 388 474 547 2800 
LENGTH OF FRAGMENT (bp) LENGTH OF FRAGMENT (bp) 
TABLE I 
Relative  promoter  activity of deletion  constructs 
Standard  deviation = d T  crL.1 (xj - $2 . n, number of independ- 
ent transfection  experiments; x#, relative  activity of one experiment; 
X, mean of relative  activities of separate experiments. 




2.8 kb 55.5 -+ 13.6 n = 4 
547 bp 
474 bp 
75.2 f 15.9 n = 10 20.0 f 8.6 n = 4 
76.1 f 7.6 n = 4 18.3 f 8.9 n = 4 
388 bp 99.8 f 6.6 n = 4 28.4 f 20.6 n = 4 
279  bp 100 
209 bp 
53.8 f 26.0 n = 6 
93.1 f 19.5 n = 5 100 
121 bp 
108 bp 
22.8 f 2.8 n = 7 84.6 f 64.9 n = 6 
6.25 f 1.3 n = 4 13.2 f 10.0 n = 6 
are  contained  in  the 279 bp immediately upstream  from  the 
first AUG. 
Promoter Activity Is Diminished in a  Nonhepatocyte  Line- 
In  order  to  determine  whether  the  promoter  element  under 
study  is  adequate  to  confer  tissue specificity, the  Factor X 
promoter-containing hGH constructs were transfected into 
HeLa (17) cells, a malignant cell line which  does not  normally 
express  Factor X. Direct  comparison of results  with  HepG2 
is difficult, since  optimal  transfection  conditions differ in  the 
two cell lines. However, maximal  activity  using  optimal  trans- 
fection  conditions  in  HeLa cells  was  only  20% of the maxi- 
mum observed with HepG2 cells. Comparison of relative 
activities  in  the two cell lines  is  also  informative (see Fig. 3). 
I n  HepG2 cells, the fragment between 209 and 388 bp up- 
stream from the  first AUG confers  maximal  promoter  activity; 
in HeLa cells, however, maximal promoter activity is seen 
with  the 209-bp fragment,  and  inclusion of the  next 179 bp of 
the promoter decreases activity to 28% of maximum. This 
reduced  expression  suggests the presence of a HeLa-specific 
negative acting element in this region, and is in marked 
contrast  to  the  results  with  the  same  fragment  in  HepG2 cells. 
Identification of Protein-binding Sites  within the Factor X 
Promoter-Within the X promoter, two  regions were selected 
for  further  study,  one  characterized by the presence of the 
putative  protein-binding  site CCAAT  (29) and  the  other by 
the  presence of the sequence ACTTTG, which is conserved 
in  the  promoters of Factors VII, IX,  and X (11). 
As a first  step, gel mobility shift  assays  using  normal  and 
mutant oligonucleotides from  these regions were carried out. 
Results  with  the  CCAAT-containing  probe  are  shown  in Fig. 
4a. The location within  the  promoter of the 30-base  oligonu- 
cleotide probe  (designated CCAAT) is  shown  on Fig. 2. Lane 
1 contains oligonucleotide probe alone; in lane 2, the  probe 
has been incubated with 10 pg of HepG2 nuclear extract. 
Three slower moving bands,  representing  protein-DNA com- 
plexes, are seen. Addition of a 15-fold excess of unlabeled 
competitor (unlabeled oligonucleotide, lane 3) markedly re- 
duces the  intensity of these  bands  and a  60-fold excess (lane 
4) eliminates  them, suggesting that  the  binding  is specific for 
the  fragment used. 
In lanes 5-7, the  same  30-mer  has been  used as probe, but 
a mutated 30-mer (mCCAAT),  in which the sequence CCAAT 
has been changed to AGCTA by random mutagenesis, is used 
as unlabeled competitor.  Note  that even at  150-fold excess, 
the  mutated sequence  does not  compete well with  the wild- 
type sequence for  binding of proteins  in  the HepG2 nuclear 
extract. There is perhaps a very  modest  decrease in the 
intensity of the slowest  moving band at 150-fold excess. When 
the mutated sequence is used as probe (lanes 8-10), the 
slowest  moving band  is  faintly  detected (lane 9), but  the  other 
bands  are  not  detected at all. This  band  is  no longer detected 
after  the  addition of a  150-fold excess of the  mutant probe. 
Thus  the slowest  moving band may result from binding at  a 
site  other  than CCAAT within  the 30-base  sequence  used as 
probe. 
Similar  studies  with  the  ACTTTG-containing  probe (see 
Fig. 2  for  location within  the  promoter)  are shown in Fig. 4b. 
Lane 1 contains probe alone and lane 2 probe and HepG2 
nuclear  extract.  Two  bands  are  apparent  in close proximity, 
with  the slower moving band being  more intense. Addition of 
15-fold excess of unlabeled competitor abolishes the  faster 
moving band  and greatly  reduces the  intensity of the slower 
moving band;  addition of a 60-fold excess of competitor abol- 
ishes  this  band as well. When  mutant 30-mers, in which the 
sequence ACTTTG  has been altered by random mutagenesis 
to GACAAT, are used as unlabeled competitors (lanes 5-7, 
designated  mACTTTG)  no reduction in  either  band is seen, 
even at 150-fold excess of competitor. When the mutant 
oligonucleotides are used as probe (lanes 8-10), no  retarded 
bands  are  seen,  confirming  that  alteration of the  ACTTTG 
site  results  in loss of the  characteristic  protein-binding  prop- 
erty of the  DNA sequence. 
Fig. 4c shows that even a single base change within the 
ACTTTG sequence can result in the loss of its protein- 
binding  property.  In  this  experiment,  binding  with  the wild- 
type sequence is  compared  to  binding  in  the pr sence of a 30- 
mer which is  identical except that  ACTTTG  has been changed 
to ACTTAG. Again, incubation of HepG2 nuclear extract 
with labeled  wild-type  probe results  in  the  generation of two 
bands, which are abolished by excess unlabeled competitor. 
When the mutant sequence (designated MT-~) is used as 
1- . ;led competitor (lanes 5 and 6), the diminution in in- 
tensity of the two bands is much less, even with a 60-fold 
excess of the  mutant oligonucleotide. Thus,  the single-base 
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FIG. 4. Gel mobility shift  assays  using normal and mutant 
sequences as probes. a, the element CCAAT in the Factor X 
promoter  binds HepG2 nuclear  proteins.  Protein-DNA complexes are 
analyzed on a 4% nondenaturing acrylamide gel. The end-labeled 
wild-type oligonucleotide 5’-GCAGGTCTCGGCTCCAATCAGGA- 
GGCCTAA-3’ is used as probe in lanes 1-7 (designated CCAAT). 
The oligonucleotide in mCCAAT is  identical  except that  the  sequence 
AGCTA has been substituted for  CCAAT by  random  mutagenesis. 
Lane 1 contains labeled  oligonucleotide  alone; in lanes 2-7, the 
oligonucleotide is incubated with 10 pg of HepG2 nuclear extract. 
Unlabeled competitor is added  in lanes 3-7 as  indicated.  Binding  to 
the wild-type probe  is  competed specifically by unlabeled wild-type 
oligonucleotide (lanes 3 and 4 ) ,  whereas binding to the probe is 
unaffected by the  addition of excess mutant oligonucleotide  (lanes 5- 
7),  except for a modest decrease in  the  intensity of the slowest  moving 
band. Lane 8 contains mutant oligonucleotide alone, and lane 9, 
mutant oligonucleotide and 10 pg of HepG2  nuclear  extract.  Only  the 
slowest moving band  is  present, suggesting that  the  protein-binding 
site within the oligonucleotide is a t  a site  other  than  the CCAAT 
sequence.  Addition of unlabeled mCCAAT (lane 10) eliminates  the 
band. b, the  element  ACTTTG  in  the  Factor X promoter  binds  hepatic 
nuclear proteins. The labeled  oligonucleotide 5”GCTGGGGC- 
GTGGACTTTGCTCCACAGCCT-3’ (designated  ACTTTG)  is used 
change  results  in  a  marked reduction in affinity for the bound 
protein(s).  In lanes 7-10, the  mutant oligonucleotide MT+A is 
used as labeled probe. A faint band corresponding to the 
slower moving band is seen with the HepG2 nuclear extract 
(lane 8), but  the intensity is markedly diminished compared 
to binding to  the wild-type sequence (compare lane 2). The 
faint band is abolished by addition of unlabeled (mutant) 
competitor, so the binding, although greatly reduced, is spe- 
cific for the fragment. 
To determine  whether  these  putative protein-binding 
site(s) within the fragments  tested have any  functional role 
in the promoter, the sites were altered by mutagenesis and 
tested using the reporter gene assays previously described. In 
all of these assays, the wild-type and mutated  fragments were 
279 bp in length, and differed from each other only at  the 
sites designated. Mutations were installed in the 279-bp wild- 
type fragment using site-directed mutagenesis and  then sub- 
cloned back into pOGH. Results, which represent the average 
of  2-6 transfection  experiments, are shown in Fig.  5. (Stand- 
ard deviations for these  experiments are shown in  Table 11.) 
Note that  substitution of  AGCTA for CCAAT within the 279- 
bp promoter reduces promoter activity to 11.8% of wild-type, 
and similarly that  the change from ACTTTG to GACAAT 
reduces promoter activity to 17.2% of wild-type. Even the 
single-base change from ACTTTG to ACTTAG reduces pro- 
moter activity to 19.2% of wild-type. In  contrast, when the 
potential Spl-binding  site (30) at  -66 to -61 was changed 
from GGGGCG to TCTATC,  no change in  promoter activity 
was seen. Thus,  the two elements, CCAAT and ACTTTG,  in 
addition to binding proteins within a HepGZ nuclear extract, 
appear to be critical for Factor X promoter activity, since 
mutations in these sequences result in a 5-10-fold drop in 
promoter activity. 
Transcription  Factor C/EBP Does Not Bind to the CCAAT 
Sequence within the Factor X Promoter-The transcription 
factor C/EBP, present in liver and adipose tissue (4, 31), 
binds a t  a  number of different DNA elements, some charac- 
terized by the presence of the sequence CCAAT. Crossley and 
Brownlee (lo), using DNase  footprinting  studies, have shown 
that  C/EBP binds to  the Factor IX promoter. We tested the 
ability of C/EBP  to bind to  the CCAAT-containing fragment 
of the Factor X promoter  in  a gel mobility shift assay. The 
labeled probe was the 30-mer designated CCAAT protein in 
the binding assay consisted of either  C/EBP  translation prod- 
uct  (1/25 of translation product from 1 pg of C/EBP  tran- 
script), or 5 ng of purified C/EBP fragment (88 COOH- 
terminal amino acids capable of binding DNA). Under several 
different sets of binding conditions, neither the  translation 
product  nor the purified protein bound to  the CCAAT  oligo- 
nucleotide, whereas both bound to a positive control sequence 
(residues -178 to +33 from the Factor IX promoter), confirm- 
as probe  in lanes 1-7. mACTTTG  is  the  same sequence  except that 
ACTTTG  has been changed  to GACAAT by random mutagenesis. 
Again, lane 1 contains labeled probe alone, and lanes  2-7, probe  and 
10 pg of HepG2  nuclear  extract.  In lanes 3-7 unlabeled competitor  is 
added as indicated, and lanes 8-10 contain mACTTTG as labeled 
probe. Two prominent bands are generated by addition of HepG2 
nuclear  extract  (lane  2) which are competed  specifically by unlabeled 
wild-type oligonucleotide (lanes 3 and 4 )  but not by the mutant 
oligonucleotide  (lanes 5-7). The  mutant oligonucleotide is  unable to 
bind  protein from the  nuclear  extract (lane 9). c, gel mobility shift 
base  change 5’-GCTGGGGCGTGGACTTAGCTCCACAGCCT-3’ 
assay.  Oligonucleotide ACTTTG  is as above. MT-A contains a  single 
within the highly conserved ACTTTG sequence. Note that MT-A 
competes poorly with the wild-type oligonucleotide (ACTTTG) for 
binding  nuclear  proteins  (compare lane 2 with lanes 5 and 6), and 
indeed appears  to have  very low affinity for nuclear  proteins (lane 8 ) ,  
compared to  the wild-type  sequence (lane 2). 
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FIG. 5. Mutations at specific elements in  the Factor X pro- 
moter  result  in a marked loss of promoter  activity. Specific 
mutations tested are  shown beneath the bar  graph. These were 
installed in the 279-bp fragment  and tested in the reporter gene assay 
as described. Results shown are the average  of at least three transfec- 
tion experiments. Mutations at the ACTTTG and CCAAT sites result 
GGGGCG has virtually no effect. 
in a marked decrease in promoter activity whereas a change at 
TABLE I1 
Relative growth hormone expression in  mutant  constructs 
Mutant construct Relative activity 2 S.D. position 
7% 





-52 19.2 f 6.6 n = 6 
A 
GGGGCG -65 + -60 90.2 f 2.1 n = 2 
TCTATC 




n, number  of  independent transfection experiments. 
ing by  gel shift Crossley and Brownlee’s earlier  DNase foot- 
printing result. Thus  C/EBP does not appear to be the  tran- 
scription factor binding to  the CCAAT- containing  element 
within the Factor  X  promoter. 
DISCUSSION 
Start  Site of Transcription-A necessary prerequisite for 
the study of the Factor X promoter is definition of the  start 
site of transcription. We used anchored PCR  to determine 
the  start site, and confirmed these data using S1 nuclease 
analysis. In  both cases the  starting material was RNA from 
normal  human liver, so that potential problems related to  the 
use of RNA from transformed cell lines (e.g. aberrant  start 
sites)  are avoided. 
Anchored PCR is a  technique which allows one to amplify 
a specific segment of DNA or RNA when sequence informa- 
tion is available for only one end of the segment. The method 
has general applicability but offers special advantages for 
mapping start sites  in genes belonging to superfamilies, since 
the  start  site is provided as sequence data, which allows the 
identification and exclusion of extraneous sequence. This is 
in  contrast  to  the potential  pitfalls of S1 nuclease mapping or 
primer extension, where there is always the concern that 
signals on  the autoradiograph may have arisen from hybridi- 
zation with a closely related transcript  rather  than  the  tran- 
script under study. 
Anchored PCR  has not been extensively used previously to 
map start sites of transcription (13). Thus we confirmed the 
results  using S1 nuclease analysis. As an additional check on 
the method, we used anchored PCR  to determine the  start 
site of transcription for human Factor IX. Using total  human 
liver RNA as  starting material, we identified two start sites, 
one at  26 bp upstream and  the  other  at 10 bp upstream from 
the first AUG. These  data  are in close agreement with those 
of Anson et al. (28), who identified a start  site 29 bp upstream, 
using S1 nuclease analysis. 
The results for the Factor  X transcript show the presence 
of multiple start sites of transcription, most clustered in  a 
segment 13  to 33 bp upstream from the first AUG. The finding 
of multiple start sites is consistent with results reported for 
other TATA-less promoters (27). The cluster of start sites 
that we report here predicts  a relatively short  5”untranslated 
segment for human Factor  X. This is similar to  the findings 
for human Factor IX (Ref. 28 and  this  report), where the 5’- 
untranslated region appears to be short, <30 bp. 
Functional Characterization of the Human Factor X Pro- 
moter-In HepG2 cells, maximal promoter activity is attained 
with a 279-bp fragment of 5’-flanking DNA (Fig. 3A). Inclu- 
sion of an additional 109 bp (388 bp fragment) results in 
virtually no change in promoter activity, while inclusion of 
additional  5”flanking  elements (beyond 388 bp)  results in a 
gradual decrease in activity. These  results  are similar to those 
previously reported for the Factor IX promoter (8) where 
maximal activity is attained using a 303-bp promoter element 
(numbering from the first AUG), and inclusion of an addi- 
tional  5‘-flanking sequence, up to 445 bp upstream from the 
first AUG, results  in  little change in  promoter activity. 
In HeLa cells, which do not express Factor X,  the  pattern 
of expression is different, with maximal activity seen with the 
209-bp fragment, and marked loss of promoter activity with 
inclusion of additional  5”flanking sequence. The 388-bp con- 
struct  has only 28.4% of the activity seen with the 209-bp 
construct. Although direct comparisons between cell lines are 
difficult, since  optimal  transfection  conditions are different, 
it should be noted that maximal GH activity for the HepG2 
cells was &fold higher than  that observed for HeLa cells. The 
relative promoter activities, and the differing patterns of 
promoter activity with addition of the fragment from -209 to 
-388 (sustained maximal levels of expression in HepG2 uersus 
reduced expression in  HeLa cells) both  point toward a possible 
tissue-specific regulatory element within this fragment. 
Analysis of promoter activity in HepG2 cells reveals that 
deletion of the 88 bp between the 209- and 121-bp constructs 
results in a 4-fold decrease in promoter activity, and deletion 
of the next 13 bp has an additional 4-fold loss of activity. 
Thus critical  promoter  elements reside in the fragment from 
-209 to -108. Whether any of these elements are tissue- 
specific is unclear, but the difference in overall promoter 
activity  in the two cell lines is consistent with the notion that 
these  elements may also possess some degree of tissue speci- 
ficity for hepatocytes. 
We chose for further study two specific elements within the 
5”flanking region: the sequence from -133 to -103, contain- 
ing the element CCAAT (at -120 to -116), and  the sequence 
ACTTTG located -56 to -51 upstream from the first ATG. 
The former was chosen because of the marked decrease in 
promoter activity resulting from deletion of this element 
(compare -121 to -108 in Fig. 3A) and  the  latter because of 
its conservation in  the promoter regions of FVII, IX, and X. 
Based on gel mobility shift assays (Fig. 4), both  elements bind 
proteins  contained in a HepG2 nuclear extract. In both cases 
specificity of binding is demonstrated by disappearance of 
15446 Factor X Promoter 
binding complexes following addition of unlabeled competitor. 
For  the more 5'-element, alteration of the CCAAT sequence 
by random mutagenesis (to AGCTA) results in a sequence 
that  cannot compete for binding to HepG2 nuclear proteins 
(lanes 5-7). When the altered sequence is used as a probe 
(lane 9) the two faster migrating complexes are entirely 
absent, indicating that  they  both require an  intact CCAAT 
sequence for binding, whereas the slowest moving complex is 
still seen, suggesting that binding for this protein does not 
require the CCAAT sequence. Further evidence of the critical 
nature of the CCAAT sequence is seen in the promoter 
activity assays displayed in Fig. 5. Alteration of the sequence 
to AGCTA within the 279-bp fragment of 5"flanking results 
in a 10-fold drop in promoter  activity. Thus a change in  the 
CCAAT element abolishes protein binding and profoundly 
reduces promoter activity of the Factor  X  promoter. Since the 
element CCAAT can serve as a recognition sequence for the 
transcription factor C/EBP, which has been shown to bind to 
a site within the F.IX promoter (lo), we wished to determine 
whether C/EBP bound to  the 30-mer spanning -133 to -103. 
Results using both the purified protein and  the  translation 
product were negative, suggesting that  the  protein(s) binding 
to this element within the X  promoter  are  distinct from this 
previously characterized liver transcription factor. 
Results for analysis of the ACTTTG  element were similar 
to those described for the CCAAT element. An oligonucleotide 
probe  spanning the sequence from -68 to -39 and containing 
ACTTTG binds  proteins from a HepG2 nuclear extract; the 
complexes are abolished by the addition of unlabeled compet- 
itor. Mutant sequences in which ACTTTG  has been changed 
to GACAAT cannot compete for binding (lanes 5-7) nor can 
they bind protein from the nuclear extract (lane 9). The 
substitution of even a single nucleotide within this sequence 
(ACTTTG + ACTTAG) results in  the complete loss of the 
faster moving band (lane 8). In  the reporter gene assay (Fig. 
5) both of these  mutations  result in a %-fold loss of promoter 
activity compared to wild-type. Again loss of ability to bind  a 
nuclear protein (or proteins) is associated with a dramatic 
decrease in  promoter  activity for the sequence under study. 
The point  mutation  in the ACTTTG sequence is identical 
to a  naturally occurring mutation described in  the F.IX pro- 
moter (T-A at -20, within the conserved ACTTTG se- 
quence) (32). This variant displays the Leyden phenotype, 
with absence of F.IX protein  (antigen and activity)  in affected 
children, but gradually increasing levels following puberty. 
The pathophysiology of the Leyden phenotype  remains  unex- 
plained, but further characterization of the protein which 
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